(SGMO) Sangamo Biosciences – Bull of the Day

October 16th, 2009

Sangamo Biosciences, Inc. (SGMO) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases.

We are optimistic about this novel technology. SB-509 has shown some positive results for the treatment of moderate to severe DN. We are also optimistic about other clinical programs. Further, we are impressed by the company’s strategy to monetize this ZFP technology.

We maintain our Outperform rating on shares of Sangamo based on the platform technology and the progress the company has made for both its clinical and preclinical programs. Our target price is $10.00.

Zacks Investment Research
View original at: Zacks.com News Feed

More on this topic (What's this?)
How Patient X Could Save Millions of Lives (Wall Street Daily, 10/31/11)
Sangamo Biosciences, Earnings Estimate $SGMO (Robert Weinstein Trading Blog, 10/24/11)
Biotech expert eyes Sangamo (SGMO) (Wall Street Sector Selector, 3/9/11)
Performing Pharmaceutical Stocks at NASDAQ: (SGMO, CYTR, ZLCS, VPHM, SLXP) (Penny Stock DD, 2/28/11)
Read more on Sangamo BioSciences at Wikinvest

Related Posts:

  1. (APH) Amphenol Corporation – Bull of the DayAmphenol Corporation (APH) is scheduled to release its fiscal Q3 results on October 15. The...
  2. (GES) Guess? Inc. – Bull of the DayGuess? (GES) reported better-than-expected results for the first half of 2010, thanks to strong North...
  3. (FMX) Fomento SAB – Bull of the DayWe are reiterating our recommendation on Fomento (FMX) shares given its relative immunity from the...
  4. (CYTX) Cytori Therapeutics – Bull of the DayWe continue to be very positive on Cytori Therapeutics Inc. (CYTX) and believe the company’s...


Search Posts by Tag: | | Biotechnology | Healthcare

RSS Feeds by Tag: Sangamo Biosciences Inc | SGMO | Biotechnology | Healthcare |

Other Posts by: | RSS Feed for this author